Rare Disease: 2023 in Review
As we look back at another busy year for the rare disease (RD) space, we also reflect on the continued growth of CRA’s rare disease capabilities and offerings....
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
CRA’s life sciences litigation support services are grounded in a comprehensive understanding of pharmaceutical, biotechnology, medical device, and diagnostic markets. For more than 30 years, our experts have consulted with major life science companies, law firms, and regulatory agencies around the globe. We provide clients with the industry and analytical expertise needed to solve our clients’ most complex issues.
CRA has a reputation for delivering rigorous analysis and expert testimony. Economic expertise is complemented by experience assisting life sciences companies with business and policy issues. This combination allows CRA to provide effective expert testimony and support.
Group Vice President and Life Sciences Practice Leader
Boston
+1-617-425-3357 gbell@crai.comAs we look back at another busy year for the rare disease (RD) space, we also reflect on the continued growth of CRA’s rare disease capabilities and offerings....
Charles River Associates today announced the promotions of six new vice presidents. Sean Sheridan in CRA’s Intellectual Property Practice, Eddie Li, Erika...
Andrew Tepperman is a panelist during the session titled “Damages issues in IP and life science disputes.” For more information on this event, click here.
An Interdisciplinary Program for In-House Counsel, Chief Officers, and Strategic Investors Hosted by Dechert and Co-sponsored by Charles River Associates Join...